Gilead Waives Acquisition Option As Pionyr Explores Other Strategies
$315m Buy Off The Cards
Gilead has waived its option to acquire Pionyr, allowing the US biotech to explore other partnerships and financing opportunities as it advances a promising pipeline of macrophage-targeting antibodies.
